Selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the milan criteria

Annals of Surgery

Volumn 263, Issue 5, 2016, Pages 842-850

  Lee, Jeong Hoon ^a   Cho, Yuri ^a,b   Kim, Hwi Young ^c   Cho, Eun Ju ^a   Lee, Dong Hyeon ^a   Yu, Su Jong ^a   Lee, Jae Woo ^a   Yi, Nam Joon ^c   Lee, Kwang Woong ^c   Kim, Seoung Hoon ^d   Kim, Jong Man ^a   Joh, Jae Won ^a   Teperman, Lewis W ^e   Park, James S ^e   Kim, Yoon Jun ^a   Suh, Kyung Suk ^a,c   Yoon, Jung Hwan ^a  

^a Seoul National University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d National Cancer Center   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Beyond the Milan criteria; Hepatocellular carcinoma; Living donor liver transplantation; MoRAL score

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; FLUORODEOXYGLUCOSE F 18; GLYPICAN 3; TUMOR MARKER; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER TRANSPLANTATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORAL SCORE; MULTICENTER STUDY; OVERALL SURVIVAL; PERINEURAL INVASION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; SOUTH KOREA; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR RECURRENCE;

ADULT; AGED; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPUBLIC OF KOREA; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84954500639     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001578     Document Type: Article

References (44)

1. Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15:1001-1007.
2. Chen CL, Cheng YF, Yu CY, et al. Living donor liver transplantation: the Asian perspective. Transplantation. 2014;97(suppl 8):S3.
3. Lee HS. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: the controversies continue. Dig Dis. 2007;25:296-298.
4. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15:270-285.
5. Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl. 2003;9:693-696.
6. Choi HJ, Kim DG, Na GH, et al. Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma. Transplant Proc. 2012;44:399-402.
7. Gondolesi GE, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg. 2004;239:142-149.
8. Vitale A, Morales RR, Zanus G, et al. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol. 2011;12:654-662.
9. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986-994.
10. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832-838.
11. Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53: 1020-1022.
12. Miller CM, Smith ML, Diago Uso T. Living donor liver transplantation: ethical considerations. Mt Sinai J Med. 2012;79:214-222.
13. Cho JY, Suh KS, ShinWY, et al. Thrombosis confined to the portal vein is not a contraindication for living donor liver transplantation. World J Surg. 2008;32:1731-1737.
14. Chun J, Kim W, Kim BG, et al. High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant. 2010;10:1649-1659.
15. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35-43.
16. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-1403.
17. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13:1637-1644.
18. Toso C, Meeberg G, Hernandez-Alejandro R, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62:158-165.
19. Lee KW, Yi NJ, Suh KS. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience. Transplantation. 2014;97(suppl 8):S20-S23.
20. Inoue Y, Hasegawa K, Ishizawa T, et al. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery. 2009;145:9-19.
21. Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403-410.
22. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165.
23. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
24. Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl. 2003;9:700-702.
25. Neuberger J. Developments in liver transplantation. Gut. 2004;53:759-768.
26. Yang HJ, Lee JH, Lee DH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology. 2014;271:909-918.
27. Nishikawa H, Inuzuka T, Takeda H, et al. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol. 2011;11:143.
28. Wang JH, Wang CC, Hung CH, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56:412-418.
29. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129-137.
30. Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598-609.
31. Todo S, Furukawa H. Japanese Study Group on Organ T. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240:451-459.
32. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228:479-490.
33. Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006;81:1633-1639.
34. Chan EY, Larson AM, Fix OK, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl. 2008;14: 956-965.
35. Pote N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-854.
36. Suehiro T, Sugimachi K, Matsumata T, et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer. 1994;73:2464-2471.
37. Bae HM, Lee JH, Yoon JH, et al. Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer. 2011;11:435.
38. Xu JF, Liu XY. PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition. J Hepatol. 2015;63:1040-1041.
39. Furukawa M, Nakanishi T, Okuda H, et al. Changes of plasma des-gammacarboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer. 1992;69:31-38.
40. Kakizaki S, Sohara N, Sato K, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol. 2007;22:518-522.
41. Huh K, Choi SY, Whang YS, et al. Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma. J Korean Med Sci. 1998;13: 306-310.
42. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132:931-937.
43. Park MS, LeeKW, SuhSW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceaseddonor liver transplantation. Transplantation. 2014;97:71-77.
44. Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol. 2011;55:1137-1147.